Targeting the programmed cell death-1 pathway in breast and ovarian cancer

Current Opinion in Obstetrics & Gynecology
Leisha A EmensLaureen S Ojalvo

Abstract

Immune checkpoint blockade is changing cancer therapy. Targeting the programmed cell death-1 (PD-1) pathway releases T cells from inhibitory signals within the tumor microenvironment, thereby activating a latent antitumor immune response. Here, we review the biology underlying the activity of PD-1/programmed cell death-ligand 1 (PD-L1) antagonists, and data describing their clinical activity in breast and ovarian cancer. Several antagonists of PD-1 and PD-L1 have been tested in breast and ovarian cancer. These drugs are generally well tolerated, with some immune-related adverse events that are typically easily managed. Objective response rates generally range from about 10 to 20% in both breast cancer and ovarian cancer, with durable responses noted in multiple trials. Selecting patients with PD-L1 expression by cells within the tumor microenvironment appears to enrich for responses. These agents are under accelerated development based on these promising early data. Monoclonal antibody-based blockade of the PD-1 pathway results in objective and durable clinical responses in a subset of patients with breast or ovarian cancers, particularly those with PD-L1-positive cells within the tumor microenvironment. Current priorities are ...Continue Reading

References

Jan 17, 2003·The New England Journal of Medicine·Lin ZhangGeorge Coukos
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Junzo HamanishiShingo Fujii
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Feb 12, 2014·Cancer Immunology, Immunotherapy : CII·Shenyou SunKunwei Shen
Apr 26, 2014·Cancer Immunology Research·Elizabeth A MittendorfGheath Alatrash
May 21, 2014·Breast Cancer Research and Treatment·S MuenstS D Soysal
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvia AdamsSunil S Badve
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Nov 14, 2014·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Zoran GatalicaOmid Hamid
Dec 24, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertSibylle Loibl
Apr 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H R AliC Caldas
Sep 1, 2015·Seminars in Oncology·Evan J LipsonSuzanne L Topalian
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Junzo HamanishiIkuo Konishi
Nov 7, 2015·Human Pathology·Mauricio Z BaptistaJosé Vassallo

❮ Previous
Next ❯

Citations

Apr 27, 2017·Critical Reviews in Clinical Laboratory Sciences·Khalid El BairiSaid Afqir
Jul 23, 2016·International Journal of Molecular Sciences·Gloria MitticaGiorgio Valabrega
Dec 26, 2018·Clinical and Experimental Immunology·A PawłowskaI Wertel
Aug 2, 2019·Cancers·Chidalu A EdechiYvonne Myal
Aug 25, 2019·Current Treatment Options in Oncology·J Stuart Ferriss, M Yvette Williams-Brown
Aug 29, 2019·Frontiers in Immunology·Sarah NersesianJeanette E Boudreau
Aug 13, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Leisha A Emens
Jun 3, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert H VonderheideAmy S Clark
Sep 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David J MessenheimerBernard A Fox
Dec 31, 2019·Seminars in Cancer Biology·Semir VranicJuan Palazzo
Jun 21, 2017·The Breast : Official Journal of the European Society of Mastology·Gwennaëlle C Monnot, Pedro Romero
May 18, 2021·Human Antibodies·Bader Alshehri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Autoimmune Hepatitis

Autoimmune hepatitis formerly called lupoid hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells causing the liver to be inflamed. Discover the latest research on autoimmune hepatitis here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

© 2022 Meta ULC. All rights reserved